April 2022

Contents

Editorial

• HTB April 2022 (1 April 2022)

Conference reports

• 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports

• CROI 2022: Webcasts now online and open access

• CROI 2022: Islatravir studies for HIV treatment and PrEP

• CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART

• CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa

• CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses

• CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART

• CROI 2022: UK study shows PEP is started earlier using home starter packs

• CROI 2022: Summary of 14 key studies on HIV and liver disease

• CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs

Antiretrovirals

• US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents

HIV prevention and transmission

• HIV vaccine study using mRNA technology starts in the US

• South Africa approves dapivirine vaginal ring for HIV prevention

COVID-19: HIV and COVID-19 coinfection

• BHIVA statement on fourth vaccine dose for people living with HIV in the UK

COVID-19: vaccine research

• Temporary protection against omicron needs mRNA booster: limited data for those at highest risk

PDFs

• HTB: no. 4 (1 April 2022) PDF downloads